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Abstract
Development of relapse remains a problem for further improvements in the survival of pedi-
atric AML patients. While virtually all patients show a good response to initial treatment,
more patients respond poorly when treated at relapse. The cellular characteristics of leuke-
mic blast cells that allow survival of initial treatment, relapse development and subsequent
resistance to salvage treatment remain largely elusive. Therefore, we studied if leukemic
blasts at relapse biologically resemble their initial diagnosis counterparts. We performed mi-
croarray gene expression profiling on paired initial and relapse samples of 23 pediatric AML
patients. In 11 out of 23 patients, gene expression profiles of initial and corresponding re-
lapse samples end up in different clusters in unsupervised analysis, indicating altered gene
expression profiles. In addition, shifts in type I/II mutational status were found in 5 of these
11 patients, while shifts were found in 3 of the remaining 12 patients. Although differentially
expressed genes varied between patients, they were commonly related to hematopoietic
differentiation, encompassed genes involved in chromatin remodeling and showed associa-
tions with similar transcription factors. The top five were CEBPA,GFI1, SATB1, KLF2 and
TBP. In conclusion, the leukemic blasts at relapse are biologically different from their diag-
nosis counterparts. These differences may be exploited for further development of novel
treatment strategies.
Introduction
In high income countries, the vast majority (over 90%) of pediatric acute myeloid leukemia
(AML) patients achieve complete remission (CR) with current intensive chemotherapy proto-
cols [1]. However, even with optimal therapies, 30–40% of patients relapse and face a dismal
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prognosis [2–4]. Long term survival rates have only marginally increased over recent decades
and stabilized at approximately 65% [5].
Approximately 85% of the patients show a good early response to the initial induction treat-
ment in terms of blast reduction [6,7]. However, a poor response at initial diagnosis [6,7] and/
or later at relapse [4] is among the strongest adverse prognostic factors for outcome in pediatric
AML [8]. Apparently, therapy is insufficient to relieve over a quarter of the patients from a bur-
den of persistent leukemia that causes relapses and fatal outcome.
A number of cell-biological factors determined at initial diagnosis are known to be associat-
ed with an increased risk of relapse, including genetic characteristics such as abnormal karyo-
type (e.g. certain 11q23 translocations or monosomy 7 [9,10]) or gene mutations such FLT3/
ITD andWT1 [11]. Moreover, aberrant gene expression (e.g. EVI-1, BAALC,WT1) has also
been reported to be associated with the risk of relapse [12,13]. The mechanisms by which these
factors act in relapse development are largely unclear.
The mainstay of salvage regimens in relapsed AML is, as in initial treatment, cytarabine and
anthracycline based [2,14], hence drug resistance is likely to play a role in relapse development.
Although pharmacological factors may be involved in resistance to therapy [15], cellular drug
resistance is thought to contribute to poor response to therapy as well [16,17].
Previous studies with paired initial and relapsed AML samples showed that the mutational
status [18], cytogenetics [19,20] and cell surface protein expression [21,22] of AML cells may
change during treatment in a large portion of patients (>40%). This has been attributed to the
large heterogeneity of initial AML in which many different subclones may reside with different
biological properties and mutational profiles [23]. During therapy, chemoresistant clones are
selected and this clonal evolution results in a relapse consisting of cells with a common founder
but for the remainder is divergent from the initial AML [24]. The cells that are selected to sur-
vive therapy should also be capable to re-initiate the leukemia, hence these cells have by defini-
tion a immature stem cell like phenotype. That is in line with our own findings that the relapse
initiating cells present at diagnosis commonly resided in the CD34+/CD38- subpopulations
[25]. So, many biological differences are crucial in the development of relapse, however, the
precise biological background of AML relapse remains largely elusive. More detailed knowl-
edge on the specific characteristics of the relapsed AML cells is required warranting
further investigation.
In this exploratory study, we determined differences in genome wide gene expression of cor-
responding initial and relapse AML samples to find genes and gene expression profiles that
play a role in development of relapse. The contribution of mutational shifts to differential gene
expression was evaluated and molecules and pathways related to relapse development that
were commonly affected in patients were identified.
Material and Methods
Patients
We studied initial and corresponding first relapse samples (N = 46) of 23 pediatric AML pa-
tients. Viably frozen bone marrow or peripheral blood samples from pediatric AML patients
were provided by the Dutch Childhood Oncology Group (DCOG) and the ‘Berlin-Frankfurt-
Münster’ AML Study Group (BFM-AML SG). Patients who suffered from recurrent disease
within 2 years after initial diagnosis were selected. Clinical patient characteristics are summa-
rized in Table 1.
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Ethics statement
The initial diagnosis samples and their gene expression data were part of a previously published
data set [26]. The study was approved by the individual Institutional Review Boards in the
Netherlands (DCOG patients) and the Hannover Medical School Ethical Board (BFM patients)
according to national law and regulations and written informed consent was obtained for
all patients.
Blast enrichment
Leukemic cells were isolated by sucrose density centrifugation and non-leukemic cells were
eliminated as previously described [27]. All processed samples contained more than 80% leuke-
mic cells, as determined morphologically using cytospins stained with May-Grünwald-Giemsa
(Merck, Darmstadt, Germany). Subsequently, a minimum of 5106 leukemic cells were lysed in
Trizol reagent (Invitrogen, Life Technologies, Breda, The Netherlands). Genomic DNA and
total RNA were isolated according to manufacturer’s protocol.
Cytogenetics
Cytogenetic aberrations were detected by standard chromosome-banding analysis, and
screened for recurrent non-random genetic aberrations characteristic for AML, including
Table 1. Clinical characteristics of the 23 childhood AML patients in this study at presentation and first relapse.
Pair Sex FAB type Cytogenetics Blast% diagnosis Blast% relapse Time to relapse Follow-up time Dead
1 M M5 MLL t(10;11) 90 86 9.7 10.1 Yes
2 M M2 Normal 93 82 3.7 9.2 Yes
3 M M2 Loss Y 86 90 10.4 18 Yes
4 M M4 t(6;9) 89 88 8.5 14.8 Yes
5 M M5 Complex 88 84 8.9 9.2 Yes
6 M M1 Unknown 91 86 14.8 19 Yes
7 M M5 t(6;9) 93 89 5.7 12.3 Yes
8 M M5 t(6;21) 96 82 15.8 26.3 Yes
9 F M5 MLL t(9;11) 99 90 6.2 NA No
10 M M1 Unknown 82 93 11.4 14.9 Yes
11 M M2 AML-ETO 91 94 58.41 164.7 No
12 M M2 AML-ETO 91 91 12.6 101.2 No
13 M M2 AML-ETO 88 83 8.9 15.5 Yes
14 M M0 Complex 93 91 2.6 20.8 No
15 M M2 AML-ETO 95 97 7.7 18.5 Yes
16 F M4 t(11;20) 90 89 9.8 19 Yes
17 M M4 MLL t(10;11) 93 83 5.9 9.1 No
18 F M2 Normal 84 81 15.3 16.3 Yes
19 M M2 AML-ETO 95 93 14.1 53.7 No
20 M M4 Del 9 89 96 8.7 20.6 No
21 M M4 Normal 86 88 6.9 9.9 Yes
22 F M4 MLL t(9;11) 90 95 8.7 21.5 Yes
23 M M5 Del 7 93 92 14.4 215.7 Yes
Time to relapse and follow-up time are given in months
1patient 11 has follow-up time of > 2 years; Blast% after enrichment.
doi:10.1371/journal.pone.0121730.t001
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MLL-rearrangements, inv(16), t(8;21) and t(15;17), using either RT-PCR and/or fluorescent
in-situ hybridization (FISH).
Mutation analyses
Samples were screened for hotspot mutations in NPM1, CEPBA, FLT3, NRAS, KRAS, PTPN11,
KIT andWT1 as previously described [18].
Gene expression profiling and quality control
Integrity of total RNA was checked using the Agilent 2100 Bio-analyzer (Agilent, Santa Clara,
USA). cDNA and biotinylated cRNA was synthesized and hybridized to the Affymetrix
Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, USA) according to the manu-
facturer’s guidelines. Arrays with poor quality according to the manufacturer’s recommenda-
tions were excluded from further analysis.
Data preprocessing
We applied the variance stabilization normalization procedure (VSN)[28] to remove back-
ground signal and normalize raw data across arrays. Log2 transformed expression values were
calculated from perfect match (PM) probes only and summarized using a median polish meth-
od. The original and processed data from diagnosis and relapse samples have been deposited in
the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo) under GEO Se-
ries accession number GSE17855 [26] and GSE52891 respectively. (reviewer URL http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?token=qbszcmwwrdstxgv&acc=GSE52891).
Statistical analysis
Probes with expression intensity below 30 were excluded from further analysis for previously
mentioned reasons [29]. To identify differentially expressed probes in the VSN normalized ex-
pression values, we performed significance analysis of microarrays (SAM) [30]. We accepted a
maximal false discovery rate (FDR) of 30% of cases with a confidence interval (CI) of 80%.
Fold change expression differences of individual probe-sets between two classes (e.g. diagnosis
and relapse) were calculated as ratios of geometric means, i.e. the anti-log of the arithmetic
mean of the logs of probe-set intensities in each class. Differences between gene expression lev-
els as measured by TaqMan were determined using Wilcoxon Signed Rank test. For survival
analysis we used Kaplan-Meier analysis with log rank testing and Cox regression analysis to
calculate the Hazard Ratio (HR) using SPSS version 20. Two sided p values below 0.05 were
considered statistically significant.
Software
R (version 2.10.1) and the Bioconductor packages affy, affyQC, simpleaffy, affyPLM, and VSN
were used for quality control and preprocessing of raw data. Hierarchical clustering analysis
with average linkage was performed using Cluster 3.0 [31] and visualized using Gene-E (http://
www.broadinstitute.org/cancer/software/GENE-E/). Class comparison tests and class predic-
tion tests were performed using the Biometric Research Branch Arraytools 4.2.1. Pathway anal-
ysis was performed using Ingenuity Pathway Analysis 7.5 software (Ingenuity Systems,
Redwood City, CA, USA) based on the Ingenuity Pathways Knowledge Base. For details on our
bio-informatical analyses, we refer to S1 Supplementary Information.
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Real-time quantitative PCR
The expression data for 5 selected genes (TLE4,MALAT1, NUMB, EIF4E3 and HIST1H1C)
were validated using real-time quantitative PCR in 7 independent AML patients of whom we
had both initial and relapse samples available for these additional experiments. The GUS gene
was used to normalize for differences in input cDNA. Pre-developed TaqMan Assays were
used (Applied Biosystems, Foster City, CA, USA) and reactions were run on an ABI 7500
(Roche Diagnostics, Almere, The Netherlands) according to manufacturer’s description. Each
sample was run in triplicate and the expression ratios were calculated using the ΔΔCT method
after prior validation of the method for each target. Bone marrow from 2 healthy individuals
was used as a reference for relative gene expression levels.
Results
Genome wide gene expression profiling was performed for initial leukemia and corresponding
relapse samples (N = 46) of 23 pediatric AML patients. The majority (19 out of 23 patients,
79%) of the patient group was male, the median age at presentation was 13.2 years and patients
belonged to standard, intermediate and poor cytogenetic risk groups. Seventeen patients (74%)
died after relapse. Overall patient characteristics are summarized in Table 1 and described
more in detail in S1 Table.
We screened for mutations in a selected panel of genes (NPM1, CEPBA, FLT3, NRAS,
KRAS, PTPN11, KIT andWT1) that were previously shown to associate with outcome in AML
[11,18] in both the initial and corresponding relapse AML samples; results are shown in S1
Table. Analogous to our previous observations [18] both gains and losses of mutations between
initial and relapse AML samples occurred in 8 out of 23 (35%) patients. In 22 out of 23 patients
cytogenetic analysis was successfully performed on initial diagnosis samples according to stan-
dard clinical practice. Cytogenetic analysis at relapse is not part of routine diagnostics at the
time of relapse treatment and was therefore not available for all patients. Cytogenetic data was
available for both initial and relapsed samples in 10 cases. In these paired samples, the major
chromosomal rearrangements remained stable compared to diagnosis, although additional cy-
togenetic aberrations were observed (S1 Table).
Comparison of initial with relapse expression profiles
To evaluate how well the relapse samples of individual patients resembled the corresponding
initial sample, unsupervised hierarchically clustering was performed using a ‘one minus’ cen-
tered correlation and average linkage. For this analysis GEP data of all 46 patient samples were
preprocessed and probe sets were selected with a 1.5 fold variation in at least 2 samples. Fig 1
depicts how samples cluster together. The correlation between the initial and relapse samples
with a patient varied between rs = 0.15 and rs = 0.75 (as illustrated by the difference in length of
the branches in Fig 1). In 11 out of 23 patients (48%) the GEP of the relapse sample did not
cluster together with the GEP of the initial sample. In 9 out of these 11 patients, the GEP of the
initial sample was observed to cluster more than one branch away from the corresponding re-
lapse GEP, indicating dissimilar GEP between the two disease stages for these individual pa-
tients. Remarkably, 5 out of these 9 paired samples (55%) also showed a shift in mutational
status between the initial leukemia and relapse sample (Fig 1). Four out of the 9 patients
showed a lack of correlation between initial leukemia and relapse GEP, despite a stable muta-
tional status. It cannot be excluded that mutations in other genes than the currently investigat-
ed genes are involved and have changed, which was not detected here.
In 12 out of the 23 patients, initial and relapse samples clustered together, indicating similar
GEP at both disease stages. In 3 out of these 12 patients (25%) mutational shifts of the analyzed
Gene Expression in Pediatric Relapsed AML
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genes were observed. In our previous studies we found a relation between mutational shifts and
a shorter time to relapse (TTR) [18,32]. Interestingly, this was corroborated in the current
study in which patients with a GEP shift at relapse had a shorter TTR (median 8.7 vs 10.4
months), although not significant (P = 0.43), which may be due to the outlier relapse time of
patient 11 (58.4 months). This mutational shift might imply a second malignancy but that can-
not be concluded based on our current data but would require deep sequencing analysis. De-
spite the small patient number, we did also confirm our previous finding of a significant worse
OS in patients that show mutational shifts (log-rank: P = 0.04, Hazard ratio: 2.8, P = 0.05).
Differentially expressed genes in initial and relapse pediatric AML
samples
To first assess differential expression of individual genes that discriminate between initial and
relapse samples in general, irrespective of patient specific characteristics, we compared GEP of
the 23 initial with the 23 relapse AML samples (comparing the class of diagnosis to the class of
relapse expression profiles). Even with a low stringency false discovery rate of 0.3, SAM analy-
sis yielded only few individual genes that were discriminative between initial and relapse sam-
ples (S1 Fig). Stratification according to cytogenetic subgroups did not improve these results
(data not shown). With the aim to find relapse specific gene expression signature rather than
individual genes that discriminate relapse from initial samples, we developed a multi-gene clas-
sifier using BRB Arraytools. The classifier consisted of 306 probes (228 known genes) that were
discriminative between initial and relapse AML samples with a high sensitivity (70–83% de-
pending on the cross validation method applied, P306th probe = 0.005, S3 Table, Fig 2). Hence,
there seems to be a set of genes that defines relapsed AML.
To confirm these findings, we validated the differential expression of TLE4,MALAT1,
NUMB, EIF4E3 HIST1H1C by Taqman RT-PCR in 7 independent sets of paired initial and re-
lapse AML samples (n = 14, Fig 3). In these samples, the expression of TLE4 was increased in 5
out of 7 cases (P = 0.06) and inMALAT1, NUMB and EIF4E3 in 4 out 7 cases (P = 0.31). The
expected relative downregulation of the expression of HIST1H1C in relapse samples compared
to diagnosis samples was found in 4 out of 7 cases (but not statistically significant: P = 0.74).
Since AML patients are genetically heterogeneous [8,33] we hypothesized that relevant dif-
ferences are better studied by focusing on individual patients and their patient specific differ-
ences between diagnosis and relapse. To this end, we individually compared gene expression
profiles of the initial samples with the corresponding relapse sample of each patient (n = 23).
This allows taking patient specific differences between diagnosis and relapse samples into
Fig 1. Hierarchical clustering dendrogram of paired initial and relapse AML samples. Similarity of GEP: Black bars indicate paired samples with GEP
that correlate according to hierarchical cluster analysis. Grey bars indicate paired samples with mutational shifts between initial and relapse AML samples.
doi:10.1371/journal.pone.0121730.g001
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Fig 2. Heat map of probe-sets that distinguish initial from relapse AML samples. The black top bar indicates initial AML samples and the top gray bar
represents relapse AML samples.
doi:10.1371/journal.pone.0121730.g002
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account. Differential gene expression was determined for each individual patient by selecting
genes that minimally had a two-fold change in expression level between diagnosis and relapse.
In all 23 patients, more genes were up-regulated (median 422, range 40–1743 genes) than
down-regulated (median 277, range 53–1326 genes) at relapse. Ingenuity pathway analysis was
performed for these differentially expressed genes for each patient. The three most commonly
affected pathways involved inflammatory disease related networks (21/23 patients), cell move-
ment and proliferation networks (15/23 patients) and chromatin disorder networks (13/23
patients).
In addition, Inqenuity pathway analysis for each individual patient predicted which tran-
scription factors (TF) could be responsible for the observed gene expression patterns based on
experimentally observed relationships between TF and gene expression. Prediction of TF in-
volvement in gene expression patterns was performed based on a p-value of overlap<0.05 be-
tween our probe lists and the Ingenuity TF related gene expression database. From the 23 lists
of TF for each patient, we determined which TF genes were commonly involved between the
23 patients (S4 Table). The top 5 TF and their associated target genes that were differentially
expressed with robust p-values of overlap in our data in the majority of patients are listed in
Table 2. The expression changes between diagnosis and relapse of these TF target genes were
both mixed in up- and down-regulated among the different pairs, except for CDKN1A, which
was up-regulated in relapse in all 6 pairs.
Fig 3. TLE4, MALAT1, NUMB, EIF4E3 and HIST1H1C relative mRNA gene expression levels in an independent set of 7 paired diagnosis and
relapse samples.
doi:10.1371/journal.pone.0121730.g003
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The above described results implicate molecules and pathways that are involved in epigenet-
ics. In concordance with these observations, differential expression of histone variant genes
was observed in all analyses (Fig 2, S1 Fig) and in the differential gene expression profiles of in-
dividual patients. In addition, regression analysis showed that the expression of individual his-
tones variants correlated strongly with the expression of other cell cycle independent histone
variants (S2 Table).
Discussion
Improvements in OS for AML are likely to come from personalized targeted treatment ap-
proaches that aim to eradicate persistent leukemia. With the aim to elucidate factors that char-
acterize pediatric relapsed AML, we performed a genome wide gene expression study on both
initial and relapsed AML samples from 23 patients.
In 11 out of 23 (~48%) initial and relapsed AML samples the GEP did not culminate in the
same cluster (Fig 1) and hence differed significantly. Notwithstanding this fact, also in cases
where the GEP of initial and relapse samples did cluster together, differentially expressed genes
could be identified. Consequently, genes were identified in several biological pathways that are
relevant for relapse development. In addition, their underlying transcription factors could be
recognized that were changed between initial diagnosis and relapse within each patient. In the
majority of patients (86%), CEBPA transcription factor related gene expression had changed at
relapse. CEBP transcription factors play a crucial role in hematopoiesis [34]; it is indispensable
for differentiation of myeloid progenitors along the granulocytic lineage [35,36]. Regulation of
lineage-specific gene expression is known to occur via direct interaction with the basal tran-
scriptional apparatus (TBF/TFIIB), but also via interaction with the SWI/SNF chromatin re-
modeling complex that modulates gene expression in an epigenetic manner [37]. Different
types of CEBPAmutations are implicated in leukemogenesis [38,39] and confer a good progno-
sis subgroup in both adult and pediatric cytogenetically normal AML [40,41]. In our selected
relapsed AML patient group, only one patient showed a single CEBPAmutation. It has also








Top target molecules in data set (portion of patients)
CEBPA 2.6 x10-5 87 MPO(12/20), S100A9(12/20), ID2 (11/20), SOD2 (11/20), ANXA1 (11/20), CXCR4 (10/
20), BTG1 (10/20), H1FX (10/20)(2.0E-03–1.5E-09)
GFI1 8.2E-03 69 IL8 (14/16), ELANE(10/16), AZU1(9/16), RB1 (8/16), CDKN1A (6/16), SERPINA1(6/
16)(4.4E-02–1.1E-05)
SATB1 4.33E-03 69 HBB (12/16), HSPAA90 (11/16), RGS1 (11/16), CLEC2B (8/16)
(2.7E-03–4.6E-05)
KLF2 7.1E-03 65 IL8 (13/15), CCL23(12/15), CCL4(8/15),IL1B(7/15),PTGS2(7/15),SELL(7/15)
(2.3E-02–1.2E-05)
TBP 3.1E-03 61 TNFAIP3 (14/14), NFKBIA (10/14), IER3 (9/14), BCL2 (5/14), HLA-A (5/14)
(4.7E-02–5.9E-05)
In particular, CEBPA, GFI1 and SATB1 that were affected in 20, 16 and 15 out of 23 patients, respectively. Either one of these transcription factors was
predicted to be involved in the differential gene expression proﬁles of all 23 patients. Network visualization plots show which transcription factors were
involved and their target molecules that were at least 2 fold differentially expressed for individual patients (S2 Fig). For example, in patient 3, differential
gene expression of the target molecules was predicted to result primarily from CEBPA, GFI1, SATB1 and TBP1 activation/ inhibition (Fig 4). In addition,
other transcription factors, such as CEBPD, BCRA1, MYC, SRF, and TAF4B were also signiﬁcantly involved in this patient.
doi:10.1371/journal.pone.0121730.t002
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been shown that the normal function of CEBPA in hematopoietic differentiation can be altered
for example via oncogenic lesions [42], fusion proteins [43,44] or epigenetic alterations [45].
This may explain why in our study, genes that are regulated by CEBPA often showed an altered
expression, while CEBPA expression itself was not significantly changed. For example, the cell
surface glycoprotein CD9 is down regulated in bi-allelic mutated CEBPA[46] and its expression
was also down regulated in our relapsed AML samples. Commonly, CD9 has a low expression
on CD33 positive myeloid progenitors and plays a role in the regulation of cell differentiation,
growth and motility [47]. Likewise, other genes are suggestive of a more primitive phenotype
of the relapse cells such as the lower expression in relapse samples when compared to their in-
dividual initial AML samples of differentiation markers CD14, CD58 and also CXCR4, which is
usually low in immature cells. (S3 Table). In addition, these results indicate a CEBPA transcrip-
tion factor related change in differentiation status of leukemic cell populations during disease
Fig 4. Transcription network visualization plot for patient 3. Transcription network plot showing transcription factors (outer ring/ inner ring) that are
predicted responsible for differential expression of shown target molecules (middle ring) between diagnosis and relapse of patient 3. A few transcription
factors (CEBPA,GFI1, SATB1 and TBP) are responsible for the major changes in the differentially expressed target molecules.
doi:10.1371/journal.pone.0121730.g004
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progression. This may result in more primitive characteristics of the leukemic blast compart-
ment at relapse when compared to presentation. Moreover, this implies a potential benefit for
relapsed AML patients to receive therapy, that restores CEBPA related gene expression or nor-
mal differentiation, e.g. by gene therapy, nanoparticle based delivery of functional CEBPA or
small molecule modulators of CEBPA or its downstream signaling [48].
Another transcription factor of which the target gene expression levels were commonly (22
out of 23 patients) deregulated between initial and relapsed AML samples, was SATB1. This
transcription factor is thought to be a key epigenetic modifier that links higher-order chroma-
tin organization with gene regulation [49]. It regulates for example the expression of globin
gene cluster [50], many cytokines [51], plays a role in hematopoietic differentiation [50,52–54]
and is implicated in a variety of cancers and cancer progression [55,56].
We validated the differential expression of five genes (TLE4,MALAT1, NUMB, EIF4E3 and
HIST1H1C) of our 306 probe set classifier and class comparison tests. The Groucho corepres-
sor TLE4may have a role as a tumor suppressor gene in the subgroup of AML-ETO patients,
where its loss may promote survival and proliferation of leukemic cells [57]. Knockout studies
in mice suggest an essential role for TLE4 in hematopoiesis [58]. A causal role of increased
TLE4 expression at relapse as observed in our study remains to be elucidated. High expression
levels of the long non coding RNAMALAT1 are associated with aggressive proliferation, me-
tastasis and recurrence in a variety of cancers [59–61]. The observed down regulation of his-
tone variant gene expression levels in a subset of patients (e.g. HIST1H1C)may point at altered
epigenetics in relapsed AML [62]. Histone variants may play a role in hematopoietic differenti-
ation [63] and the expression of specific variants may be associated with leukemia [64]. Their
functions are various, e.g. in the response to growth factors [65] or DNA damage response re-
lated apoptosis [66]. The expression of histone variants may be influenced by drug exposure
[67] and may play a role in the tolerance to toxins [68]. These properties of histones have been
exploited in the development on recombinant human histone 1.3 (rhH1.3) as a cancer thera-
peutic agent, which was shown to induce apoptosis in leukemia cells by rupture of the plasma
membrane. This drug was applied in a phase II trial for adult relapsed AML [69].
The observed changes in gene expression from diagnosis to relapse and the patterns of clus-
tering may be explained by the emergence at relapse of minor clones with different genetic
make-up when compared to bulk of AML cells at diagnosis [24]. We have shown earlier that
such minor clonal populations can be isolated retrospectively from diagnosis samples by FACS
sorting. Besides a relapse specific mutational status, these cells expressed immunophenotypic
markers that were specific for the bulk of leukemic cells at relapse [25]. Our current study is
limited in the number of genes in which the presence of mutations was tested. In addition to
changes that are causal in relapse development, also circumstantial differences may occur dur-
ing the selection of a specific clone at relapse. Therefore, common relapse specific mutations
and relapse specific gene expression profiles should be assessed in depth by next generation
RNA sequencing of minimal residual disease cells that are likely to harbor the cells that initiate
relapse.
In conclusion, we show a variable differential gene expression between initial and relapsed
AML sample of individual patients. One group of patients shows a tumor evolution by which
resemblance between initial diagnosis and relapse gene expression profiles is lost (11 out 23 pa-
tients). The remainder of patients showed a more similar initial diagnosis and relapse gene ex-
pression profile, however, relapsed AML samples still have specific GEP that discriminate it
from initial AML. The multiple pathways that were affected in individual patients may result
from an epigenetic deregulation as suggested by observed the CEBP and SATB1 transcription
factor related differential gene expression and the diminished expression of e.g. histone vari-
ants at relapse. Our findings are in line with the current notion that the eradication of cells
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with stem cell like properties is essential for the prevention and probably also the treatment of
relapse [70]. Therefore, the currently available biological characteristics of relapsed AML
should be exploited in the application and development of novel strategies that may prevent re-
lapse or improve salvage therapies.
Supporting Information
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